Latest From Yuhan Corp.
New clinical trial approval data show that early-stage studies of novel drug candidates by South Korean pharma and biotech firms sharply increased in 2018, underlining the industry’s ongoing shift towards innovation. Trials of oncology drugs continued to dominate, while clinical work in rare disorders such as hemophilia and Crohn’s disease has noticeably increased.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging biopharmaceutical companies that have received venture funding. This month’s column covers deals announced January and February 2019.
News of 5AM's two latest venture funds follows the launch of Longevity Vision Fund as well as LA BioMed's and RUNLABS’ announcements that they will open new incubators in 2019. Also, Passage Bio launches with $115.5m, but the largest recent VC deal was HaiHe's $146.6m financing.
- Therapeutic Areas
- Blood & Coagulation Disorders & Products
- Infectious & Viral Diseases
- Metabolic Disorders
- South Korea
- Pacific Rim
- Parent & Subsidiaries
- Yuhan Corp.
- Senior Management
- Jung Hee Lee, Pres. & CEO
- Contact Info
Phone: 2 828 0181
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.